BCRX BioCryst Pharmaceuticals Inc.

8.26
-0.33  -4%
Previous Close 8.59
Open 8.54
Price To Book 12.52
Market Cap 905635023
Shares 109,641,044
Volume 501,322
Short Ratio
Av. Daily Volume 585,968

SEC filingsSee all SEC filings

  1. 8-K - Current report 181194303
  2. S-8 - Securities to be offered to employees in employee benefit plans 181171974
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169434
  4. 8-K - Current report 181161586
  5. 8-K - Current report 181148877

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 21, 2017.
RAPIVAB (peramivir injection)
Acute uncomplicated influenza to pediatric patients
Phase 2 trial to be completed 1Q 2019.
BCX7353 - ZENITH-1
Angioedema attacks in patients with hereditary angioedema (HAE)
Phase 3 data due 2Q 2019.
BCX7353 - APeX-2
Reduce or eliminate attacks in HAE patients
Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Approved Dec 22 2014
RAPIVAB (peramivir)
INFLUENZA ACUTE
Dosing of first patient in long-term safety trial announced February 28, 2018.
BCX7353 - APeX-S
Hereditary angioedema (HAE)

Latest News

  1. New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
  2. BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
  3. Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT
  4. BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
  5. BioCryst to Present at Upcoming Investor Conferences
  6. BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates
  7. BioCryst: 3Q Earnings Snapshot
  8. BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
  9. Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q3 Earnings Expected to Decline
  10. BioCryst to Report Third Quarter 2018 Financial Results on November 6
  11. Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  12. Grifols (GRFS) Surges: Stock Moves 5.4% Higher
  13. BioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
  14. What Sarepta Therapeutics’ Valuation Trend Indicates
  15. Here's Why BioCryst Pharmaceuticals Rose 21.3% in August

SEC Filings

  1. 8-K - Current report 181194303
  2. S-8 - Securities to be offered to employees in employee benefit plans 181171974
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169434
  4. 8-K - Current report 181161586
  5. 8-K - Current report 181148877
  6. DEF 14A - Other definitive proxy statements 181094468
  7. PRE 14A - Other preliminary proxy statements 181075680
  8. 8-K - Current report 181072437
  9. 8-K - Current report 181056673
  10. 8-K/A [Amend] - Current report 181051815